# Weiss Ratings

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/weiss-ratings
Canonical HTML page: https://getbiobrief.com/entity/weiss-ratings

## Timeline

- **2026-08-23**: Wall Street Zen upgrades both stocks to Hold — Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
- **2026-08-14**: Silexion reports quarterly results — Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-08-14**: Enveric reports quarterly loss — Enveric Biosciences reported EPS of -$0.76 for the quarter.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-07-31**: RBC raises CTNM target to $23 — Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
- **2026-07-30**: Contineum reports Q2 results — Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
- **2026-07-29**: Maxim Group downgrades to Hold — Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
- **2026-07-29**: Weiss Ratings upgrade — Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
- **2026-07-17**: Weiss Ratings reiterates Sell — Restated a 'sell (e+)' rating on MBRX shares in a research note
- **2026-07-17**: Weiss Ratings reiterates Sell ratings — Weiss Ratings restated a Sell (d-) on CTNM and a Sell (e+) on ENVB.
- **2026-07-10**: Shares drop 1.8% — APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
- **2026-06-30**: Schikan sells 30,712 shares — Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
- **2026-06-29**: Schikan sells 6,888 shares — Director Johannes Gerardus Chri Schikan sold 6,888 shares at $35.05, totaling $241,424.
- **2026-06-24**: Weiss Ratings reiterates sell — Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.

## Recent coverage (18 stories)

### Wall Street Zen Upgrades 2 Biotechs: CTNM at $17.19, ENVB at $1.43
2026-08-24 11:32:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Full story: https://getbiobrief.com/story/wall-street-zen-upgrades-two-biotechs-ctnm-envb-hold-bio

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### SLXN's RNAi Pipeline Faces $0.42 Stock and $5.17 EPS Loss
2026-08-16 15:01:58 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Full story: https://getbiobrief.com/story/silexion-rnai-pipeline-earnings

### Apyx Medical EPS Beats by $0.06, Stock Still Slides 1.8% to $4.38
2026-08-13 02:42:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Full story: https://getbiobrief.com/story/apyx-medical-q1-eps-beat-stock-slide-bio

### SCYX Short Interest Plunges 87.6% as ENSC Spikes 619.9%
2026-08-13 01:23:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Full story: https://getbiobrief.com/story/scyx-short-interest-plunges-87-6-ensc-spikes-619-9

### Insider Buys 7,736 HCWB Shares at $2.58; Stock 93% Below 52-Week High
2026-08-12 20:23:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A corporate insider at microcap HCW Biologics disclosed a $19,958.88 purchase of 7,736 shares at $2.58, but conflicting syndicated reports name different insiders. For biotech investors, the transaction highlights a high-risk stock trading 93% below its 52-week high despite a May EPS beat and a $30 Maxim target.
Full story: https://getbiobrief.com/story/hcwb-insider-buy-7736-shares-biotech

### Entera Bio Down 0.6% as $9.00 Analyst Target Highlights Split
2026-08-12 16:26:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Full story: https://getbiobrief.com/story/entera-bio-down-06-analyst-target-9

### PVLA Drops 12.4% on Thin Volume: Biotech Risk or 45% Upside Play?
2026-08-12 12:09:27 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Full story: https://getbiobrief.com/story/pvla-shares-down-12-4-biotech-analysis

### TLPH Upgrade: 113% Upside to $3 Target Sparks Biotech Interest
2026-08-11 12:29:49 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Full story: https://getbiobrief.com/story/talphera-upgrade-biotech-113-upside-target

### CDT Short Interest Climbs 70.8% as Biotech Cash Burn Erases 99.9% of Peak Value
2026-08-10 09:52:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Short interest in CDT Equity, the ticker for clinical-stage biotech Conduit Pharmaceuticals, jumped 70.8% after the stock plunged from a $610 high to just $0.71. With a market cap of $3.45 million and no approved products, the spike in bearish bets underscores the deep skepticism around its early-stage pipeline for autoimmune diseases and infertility.
Full story: https://getbiobrief.com/story/cdt-short-interest-biotech-penny-stock-collapse

### Agenus Upgraded to Buy After 189% Surge Off 12M Low: Analysts Eye $30 Target
2026-08-08 12:53:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Full story: https://getbiobrief.com/story/agenus-upgraded-buy-189-percent-surge

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### Biotech Sell-Off: Novavax Downgraded to Sell Despite Revenue Beat
2026-08-04 12:11:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Full story: https://getbiobrief.com/story/novavax-sell-downgrade-biotech-pharma

### $1.33M Insider Sale at Pharvaris: What It Means for HAE Drug Catalysts
2026-07-11 21:42:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Full story: https://getbiobrief.com/story/pharvaris-insider-sale-1.33m-hae-catalysts

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

### Insider Bet of $110K on Shuttle Pharma Amid 94% Crash—Pipeline Catalyst Ahead?
2026-07-05 23:48:51 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

A $110,694 insider purchase by Financial Lp Hrt in Shuttle Pharmaceuticals boosts the owner’s stake to 78,597 shares just as the micro-cap trades near $2.90 lows. For biotech investors, this accumulation could reflect confidential knowledge about the radiation sensitizer pipeline's progress.
Full story: https://getbiobrief.com/story/shuttle-pharma-insider-buy-biotech-pipeline

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.